Skip to content
‹ Back to IndustriesHealthcare

Using Open-Source Software to Drive Reliability and Security in Lab & Life Sciences

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to bringing new advancements to life. 

Health and Life Science at the Edge’s Morgan Andersen welcomed Intel Product Manager Amy Gilliam and Director of Security Communications Christopher Robinson for a discussion on open-source, everything from what it is, what the culture is like, and managing the quality of the code.

Gilliam says the culture around open source has grown to become a collaborative environment that’s enhanced over the years. Open exchange, de-centralized coding collaboration and peer review are all norms that move open source in a positive direction. “Peer review is a huge part of the open-source development process, in which developers submit code, it gets reviewed by multiple team members and project members before it gets integrated into the main code base by the maintainer,” Gilliam adds. 

From Robinson’s perspective, open source thrives because of the collaboration community. “I’ve been doing security in upstream open source for just under a decade, and I get to work with people from all around the world. We used to have a concept frequently talked about; it was called meritocracy; whereas you were contributing to these communities, people would put forth other ideas, and normally the best idea will win out. After much review and conversation, you’ll generally have better quality code because you’ve had all these different types of inputs.” 

So, how does security factor into open source when privacy is critical to a lot of work done in the health and life science world? Some essential regulations and rules govern the industry to protect human life. Gilliam says technology developers must familiarize themselves with these regulations and ensure the flexibility and capability to meet those compliance requirements now and in the future. 

“The FDA requires disclosures of software submission,” Gilliam said. “So, along with those disclosures of software, are usually calling out of risks and mitigations. Those can be cybersecurity risks, privacy risks, etc. We’re monitoring for that as we’re building software and these analytical tools that will help leverage and accelerate processes in the pharmaceutical industry.” 

Learn more about Open Source solutions by connecting with Amy Gilliam and Christopher Robinson on LinkedIn or visit Intel Health and Life Sciences. 

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AI cuts cardiologists' echocardiogram review time by 46%

AI cuts cardiologists' echocardiogram review time by 46%

Late-breaking research presented November 9 at the American Heart Association's Scientific Sessions 2026 reported that AI-drafted preliminary echocardiogram reports were comparable to human drafts. Cardiologists averaged 4.6 minutes finalizing AI drafts versus 8.5 minutes without AI. The findings are a non-peer-reviewed abstract.

  • 01Cardiologists averaged 4.6 minutes finalizing AI-drafted echo reports versus 8.5 minutes without AI, about 46% less time.
  • 02Cardiologists made substantial changes to 50.6% of AI drafts and 49.7% of human drafts.
  • 03The research used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers.

Nov 9, 2026

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

At AHA Scientific Sessions 2026 in Chicago, AI ECHO INSIGHT, WATCH-LV, PARAMOUNT and PROVAR+ showed gains in workflow efficiency, screening and treatment decisions, but none established a reduction in hard clinical events. The takeaway: the next test is proving these tools improve outcomes, especially in high-need populations, by connecting to established care.

  • 01AI ECHO INSIGHT cut echo reads 8.5 to 4.6 minutes, and PARAMOUNT changed treatment decisions, but no AI late-breaker showed fewer hard events.
  • 02ZEUS and Lp(a)HORIZON lowered their target biomarkers without reducing major cardiovascular events, a caution against treating algorithmic accuracy alone as proof of patient benefit.
  • 03Low-technology, team-based interventions such as CATCH in Colombia and Jamaica lowered blood pressure, showing the care systems AI tools must connect to.

Nov 9, 2026

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Access TeleCare pharmacist Ashley Selby describes a telehealth antimicrobial stewardship model sized to each hospital's gaps. Joint Commission Standard MM.09.01.01 and 42 CFR 482.42 require a qualified physician and/or pharmacist leader, not a full-time hire, and a 14-study meta-analysis found telehealth stewardship cut antibiotic days of therapy without changing mortality.

  • 01Joint Commission Standard MM.09.01.01, in force since January 2023, requires a physician and/or pharmacist qualified in infectious diseases or stewardship to lead the program, and its committee note allows remote participation.
  • 02The Board of Pharmacy Specialties counts more than 2,380 BCIDP pharmacists nationally, while many small hospitals still assign stewardship to pharmacists without ID training.
  • 03A 14-study meta-analysis found telehealth stewardship raised guideline adherence and cut antibiotic days of therapy, but did not significantly change mortality.

Nov 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512